Why BioNTech Stock Sank Today
_0.png?locale=de){kind=logo}
Shares of BioNTech (NASDAQ: BNTX) were sinking 6.2% lower as of 3:33 p.m. EDT on Monday. The decline appeared to result from speculation by Bernstein biotech analyst Vincent Chen that the coronavirus vaccine candidate BNT162b2 developed by BioNTech and its partner Pfizer (NYSE: PFE) could have lower efficacy than expected.
Chen thinks it's likely that BioNTech and Pfizer have had two interim analyses from the late-stage study of BNT162b2 already. The partners have publicly stated that preliminary efficacy results could be announced in October. Because the companies haven't announced any data yet, Chen suspects that the vaccine could have had a lower efficacy than initially hoped.
Image source: Getty Images.
Source Fool.com
